Using PET for therapy monitoring in oncological clinical trials: challenges ahead.

Molecular imaging with PET has emerged as a powerful imaging tool in the clinical care of oncological patients. Assessing therapy response is a prime application of PET and so the integration of PET into multicentre trials can offer valuable scientific insights and shape future clinical practice. Ho...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Nuclear Medicine & Molecular Imaging Vol. 44; pp. 32 - 41
Autores principales: Deroose, C., Stroobants, S., Liu, Y., Shankar, L., Bourguet, P.
Formato: Journal Article
Publicado: Springer Nature Aug2017 Supplement 1
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=124431338&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 124431338
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        16197070
        NPC
      jtl: European Journal of Nuclear Medicine & Molecular Imaging
      issn: 16197070
      maglogo: N
    pubinfo:
      dt: Aug2017 Supplement 1
      vid: 44
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        124431338
        143984366
        10.1007/s00259-017-3689-1
        124431338
      ppf: 32
      ppct: 9
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Using PET for therapy monitoring in oncological clinical trials: challenges ahead.
      aug:
        au:
          Deroose, C.
          Stroobants, S.
          Liu, Y.
          Shankar, L.
          Bourguet, P.
        affil: Diagnostic Imaging Branch, Cancer Imaging Program , National Cancer Institute , Bethesda USA
      sug:
      ab: Molecular imaging with PET has emerged as a powerful imaging tool in the clinical care of oncological patients. Assessing therapy response is a prime application of PET and so the integration of PET into multicentre trials can offer valuable scientific insights and shape future clinical practice. However, there are a number of logistic and methodological challenges that have to be dealt with. These range from availability and regulatory compliance of the PET radiopharmaceutical to availability of scan time for research purposes. Standardization of imaging and reconstruction protocols, quality control, image processing and analysis are of paramount importance. Strategies for harmonization of the final image and the quantification result are available and can be implemented within the scope of multicentre accreditation programmes. Data analysis can be performed either locally or by centralized review. Response assessment can be done visually or using more quantitative approaches, depending on the research question. Large-scale real-time centralized review can be achieved using web-based solutions. Specific challenges for the future are inclusion of PET/MRI scanners in multicentre trials and the incorporation of radiomic analyses. Inclusion of PET in multicentre trials is a necessity to guarantee the further development of PET for routine clinical care and may yield very valuable scientific insights.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N